Investor AB’s BioMarin Pharmaceuticals BMRN Stock Holding History

Investor AB’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Hold	3,700	–	–	﹤0.01%	7
2026 Q1	$209K	Hold	3,700	–	–	﹤0.01%	10
2025 Q4	$220K	Hold	3,700	–	–	﹤0.01%	11
2025 Q3	$200K	Hold	3,700	–	–	﹤0.01%	12
2025 Q2	$203K	Hold	3,700	–	–	﹤0.01%	13
2025 Q1	$262K	Buy	+3,700	New	+$249K	0.01%	13

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Investor AB's BMRN Position: Q2 2026 in Review

Investor AB held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 3,700 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #7.

Investor AB first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $262K in Q1 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Investor AB held 3,700 shares of BioMarin Pharmaceuticals worth $212K as of Q2 2026.
Investor AB left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Investor AB's portfolio in Q2 2026, its #7 holding.
Investor AB first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Investor AB's BioMarin Pharmaceuticals position peaked at $262K in Q1 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Investor AB's 13F filing for Q2 2026, filed 14 Aug 2026.